Cryoablation and immunotherapy of cancer.

Détails

ID Serval
serval:BIB_FF3698E414D7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Cryoablation and immunotherapy of cancer.
Périodique
Current opinion in biotechnology
Auteur(s)
Yakkala C., Denys A., Kandalaft L., Duran R.
ISSN
1879-0429 (Electronic)
ISSN-L
0958-1669
Statut éditorial
Publié
Date de publication
10/2020
Peer-reviewed
Oui
Volume
65
Pages
60-64
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Cryoablation is a hypothermic modality exercised as a focal therapy for annihilating cancer lesions. Its application leaves the ablated tumor in situ, allowing multifarious tumor antigens to be available to the host's immune system. This ensues the activation of innate and adaptive immunity against the tumor antigens. Therefore, cryoablation can be employed as an in vivo vaccination tool to fortify the impact of immunotherapies. Application of checkpoint inhibitors, toll-like receptor agonists, adoptive cell therapies and epigenetic modulators has been shown to galvanize the immune system against tumors. Preliminary data demonstrate an excellent synergy between cryoablation and immunotherapies. Future endeavors should focus on tailoring cryo-immunotherapies based on the tumor's immune signature and testing alternative approaches to circumvent treatment-associated toxicities and maximize efficacy.
Pubmed
Web of science
Création de la notice
27/02/2020 16:34
Dernière modification de la notice
13/01/2021 7:23
Données d'usage